MedTrace Logo

Phase 1 Trial of KH617

NCT05667194 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-11-27

No results posted yet for this study

Summary

KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.

Conditions

Interventions

DRUG

KH617

KH617 is s freeze-dried powder injection

Sponsors & Collaborators

  • Sichuan Honghe Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wenbin Li · Beijing Titan Hospital,Capital Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-26
Primary Completion
2030-09-30
Completion
2031-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05667194 on ClinicalTrials.gov